Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

Core Insights - Eli Lilly's Omvoh (mirikizumab-mrkz) demonstrated durable efficacy in maintaining steroid-free remission in over 90% of patients with Crohn's disease for three years, as per the VIVID-2 study results [1][2] - The treatment also showed significantly low rates of hospitalizations and surgeries in patients with both Crohn's disease and ulcerative colitis, indicating its potential to alter disease progression [1][2] - Omvoh is the only IL-23p19 inhibitor to exhibit strong and sustained efficacy over four years in ulcerative colitis and three years in Crohn's disease, with consistent monthly dosing [1][2] Efficacy and Remission - In the VIVID-2 study, 92.4% of patients maintained clinical remission, and 91.2% achieved corticosteroid-free clinical remission after three years of treatment [1][2] - Improvements in bowel urgency were noted, with 82.1% of patients experiencing a 3-point reduction on the Urgency Numeric Rating Scale (UNRS) [1][2] - Sustained improvement in inflammation was observed, with a continued decrease in inflammatory biomarkers over three years [1][2] Safety and Complications - The long-term safety profile of Omvoh remained consistent with known safety data, with common adverse events including upper respiratory tract infections and arthralgia [1][2][3] - Omvoh reduced Crohn's disease-related hospitalizations and surgeries by nearly 50% in the first 12 weeks compared to placebo, and by nearly 70% during weeks 12 to 52 [1][2] - In the LUCENT-3 study for ulcerative colitis, only one hospitalization and no surgeries were reported during the three-year extension [1][2] Regulatory and Clinical Development - Omvoh has received regulatory approvals for treating moderately to severely active ulcerative colitis and Crohn's disease in adults across 47 countries [2] - Ongoing studies are exploring combination therapies with mirikizumab to enhance treatment efficacy while maintaining long-term safety [2] - Pediatric trials for Omvoh in ulcerative colitis and Crohn's disease are also in progress [2]